Stephen Thomas Biography and Net Worth

Director of Climb Bio

Stephen currently serves as CEO and director of Sera Medicines and Starfish Medicines, and brings broad experience in drug discovery and development, business development, and capital raises. He was previously CEO and co-founder of Tenet Medicines, Inc. and served as CSO of ValenzaBio, Inc., a clinical-stage biotechnology company, up until its acquisition by ACELYRIN, INC. At ValenzaBio, Stephen led the successful development of three antibody pipeline programs in I&I from preclinical to clinical proof-of-concept, including the anti-IGF-1R monoclonal antibody lonigutamab, and served a pivotal role in overall corporate strategy and fundraisings. Prior to ValenzaBio, Stephen was CSO and co-founder of Ichorion Therapeutics, Inc., where he built and advanced a pipeline of therapies for rare pediatric diseases up until its acquisition by Cerecor, Inc.

Dr. Thomas holds a Ph.D. in organic synthesis and chemical biology from Columbia University, where he was a Bristol-Myers Squibb Fellow and NSF Predoctoral Fellow, and was previously an Amgen Scholar.

What is Stephen Basil Thomas' net worth?: The estimated net worth of Stephen Basil Thomas is at least $6.58 million as of September 15th, 2026. Dr. Thomas owns 467,969 shares of Climb Bio stock worth more than $6,579,644 as of September 18th. This net worth evaluation does not reflect any other investments that Dr. Thomas may own. Learn More about Stephen Basil Thomas' net worth.
How do I contact Stephen Basil Thomas?: The corporate mailing address for Dr. Thomas and other Climb Bio executives is 20 William Street Suite 145, Wellesley Hills MA, 02481. Climb Bio can also be reached via phone at 866-857-2596 and via email at [email protected]. Learn More on Stephen Basil Thomas' contact information.
Has Stephen Basil Thomas been buying or selling shares of Climb Bio?: Over the course of the past ninety days, Stephen Basil Thomas has sold $1,367,000.00 in shares of Climb Bio stock. Most recently, Stephen Basil Thomas sold 100,000 shares of the business's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $13.67, for a transaction totalling $1,367,000.00. Following the completion of the sale, the director now directly owns 467,969 shares of the company's stock, valued at $6,397,136.23. Learn More on Stephen Basil Thomas' trading history.
Who are Climb Bio's active insiders?: Climb Bio's insider roster includes Emily Pimblett (CAO), and Stephen Thomas (Director). Learn More on Climb Bio's active insiders.
Are insiders buying or selling shares of Climb Bio?: In the last twelve months, Climb Bio insiders bought shares 3 times. They purchased a total of 321,672 shares worth more than $779,625.64. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 100,000 shares worth more than $1,367,000.00. The most recent insider tranaction occured on September, 15th when Director Stephen Basil Thomas sold 100,000 shares worth more than $1,367,000.00. Insiders at Climb Bio own 2.6% of the company. Learn More about insider trades at Climb Bio.
Information on this page was last updated on 9/15/2026.

Stephen Basil Thomas Insider Trading History at Climb Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/15/2026	Sell	100,000	$13.67	$1,367,000.00	467,969

Stephen Basil Thomas Buying and Selling Activity at Climb Bio

Climb Bio Company Overview

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Today's Range

Now: $14.06

$13.77

$14.66

50 Day Range

MA: $14.29

$11.81

$17.84

2 Week Range

Now: $14.06

$1.54

$18.33

Volume

1,401,596 shs

Average Volume

1,568,898 shs

Market Capitalization

$807.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.09